Patent · US Active

Gene expression markers and treatment of multiple sclerosis

US11236391B2 · kind B2 · utility

0Cited by

43References

18Claims

0Family size

Assignee

Genentech, Inc. · US

Inventors

Michael J. Townsend · San Jose, US
Alvernia Francesca Setiadi · Redwood City, US
Tracy Staton · Stanford, US

Key dates

Filing date	Jul 27, 2017
Grant date	Feb 1, 2022
Priority date	—
Expiry date	Aug 9, 2037

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/52
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention concerns markers of multiple sclerosis, their use, and treatment with IL-17 antagonists, including IL-17 antibodies, of subjects with increased levels of such markers.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.